{"id":494799,"date":"2021-05-18T07:04:43","date_gmt":"2021-05-18T11:04:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/"},"modified":"2021-05-18T07:04:43","modified_gmt":"2021-05-18T11:04:43","slug":"immatics-announces-first-quarter-2021-financial-results-and-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/","title":{"rendered":"Immatics Announces First Quarter 2021 Financial Results and Business Update"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">\n          <strong>D<\/strong><br \/>\n          <strong>ata update <\/strong><br \/>\n          <strong>for<\/strong><br \/>\n          <strong> ongoing ACTengine\u00ae <\/strong><br \/>\n          <strong>IMA200 clinical trial series<\/strong><br \/>\n          <strong>demonstrate<\/strong><br \/>\n          <strong>d<\/strong><br \/>\n          <strong>first <\/strong><br \/>\n          <strong>anti-tumor activity in heavily pre-treated solid cancer patients during early phases of dose escalation<\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong>Next <\/strong><br \/>\n          <strong>ACTengine\u00ae <\/strong><br \/>\n          <strong>data update for <\/strong><br \/>\n          <strong>dose level<\/strong><br \/>\n          <strong>s<\/strong><br \/>\n          <strong>2<\/strong><br \/>\n          <strong> and <\/strong><br \/>\n          <strong>3<\/strong><br \/>\n          <strong>on track for H2 2021<\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong>P<\/strong><br \/>\n          <strong>reclinical proof-of-concept <\/strong><br \/>\n          <strong>for second TCR Bispecifics (TCER\u00ae) program IMA402<\/strong><br \/>\n          <strong>against<\/strong><br \/>\n          <strong>the frequently expressed cancer target <\/strong><br \/>\n          <strong>PRAME<\/strong><br \/>\n          <strong>announced <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong>Cash<\/strong><br \/>\n          <strong>and<\/strong><br \/>\n          <strong> cash equivalents <\/strong><br \/>\n          <strong>as well as o<\/strong><br \/>\n          <strong>ther financial assets <\/strong><br \/>\n          <strong>of <\/strong><br \/>\n          <strong>$254.0 million<\/strong><br \/>\n          <strong>(<\/strong><br \/>\n          <strong>\u20ac<\/strong><br \/>\n          <strong>2<\/strong><br \/>\n          <strong>1<\/strong><br \/>\n          <strong>6.7<\/strong><br \/>\n          <strong> million<\/strong><br \/>\n          <sup><br \/>\n            <strong>1<\/strong><br \/>\n          <\/sup><br \/>\n          <strong>)<\/strong><br \/>\n          <strong>as of <\/strong><br \/>\n          <strong>March<\/strong><br \/>\n          <strong> 3<\/strong><br \/>\n          <strong>1<\/strong><br \/>\n          <strong>, 202<\/strong><br \/>\n          <strong>1<\/strong><br \/>\n          <strong> provide cash reach into 2023<\/strong>\n        <\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Tuebingen<\/strong><br \/>\n        <strong>, Germany<\/strong><br \/>\n        <strong> and Houston, TX<\/strong><br \/>\n        <strong>, <\/strong><br \/>\n        <strong>May 18<\/strong><br \/>\n        <strong>, <\/strong><br \/>\n        <strong>20<\/strong><br \/>\n        <strong>2<\/strong><br \/>\n        <strong>1<\/strong> \u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3OUW4XZ8xSsExWuKxufF3ErMWFHuOwSgi_aLjTH9VAIYz_GMBXP0W7aI8QxE9q_EC_oz_UudMLuCfXxBmsmc_w==\" rel=\"nofollow noopener\" target=\"_blank\">Immatics<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2Ld5_yepFxEA44Zrtj-fdOdDyGqVCxax2q4hFFrJtQ0bs51ZAnJD3Mcavwt5XO6Nz16HsH7AuSoxH5gSt_ujwg==\" rel=\"nofollow noopener\" target=\"_blank\">N.V.<\/a> (NASDAQ: IMTX; \u201cImmatics\u201d), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, today reported financial results and provided a business update for the quarter ended March 31, 2021.<\/p>\n<p align=\"justify\">\u201cIn the first quarter of 2021, we reported first anti-tumor activity at the initial dose levels of our ACTengine\u00ae IMA200 clinical trial series which indicates the potential of our engineered Adoptive Cell Therapy approach. We continue to scale up enrollment by initiating additional trial sites in the US and Europe \u2013 and now look forward to treating patients at target dose levels and provide a next update in the second half of 2021,\u201d said Harpreet Singh, Ph.D., CEO of Immatics. \u201cIn addition, we are on track with our first clinical trial application for TCER\u00ae towards the end of this year. By engaging two therapeutic modalities, Adoptive Cell Therapy and TCR Bispecifics, we are aiming to address a broad cancer patient population with an urgent need for new therapeutic options.\u201d<\/p>\n<p align=\"justify\">\n        <strong>First<\/strong><br \/>\n        <strong> Quarter 202<\/strong><br \/>\n        <strong>1<\/strong><br \/>\n        <strong> and <\/strong><br \/>\n        <strong>Subsequent Company Progress<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Qltl875Ro9mO_PhzTX7wgqdTdLSUz0xY9tiL-oh4RUVpK6wXQdnsso4FITcELPQphvJvHj4gHd2Xz-cmT-qKB3YFpTrh469-1Qw0HNk_sFXcw0wPVVpawdBZS1QW078cH1X90KD0R3SN1bgB_yjQ5A==\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <em>Adoptive Cell Therapy Programs<\/em><br \/>\n        <\/a>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">ACTengine\u00ae IMA200 series &#8211; Immatics provided a <a href=\"https:\/\/investors.immatics.com\/news-releases\/news-release-details\/immatics-presents-data-update-dose-escalation-ongoing-actenginer\" rel=\"nofollow noopener\" target=\"_blank\">clinical data update<\/a><a href=\"https:\/\/investors.immatics.com\/news-releases\/news-release-details\/immatics-presents-data-update-dose-escalation-ongoing-actenginer\" rel=\"nofollow noopener\" target=\"_blank\"> from three ongoing ACTengine\u00ae Phase 1 trials<\/a> for its engineered Adoptive Cell Therapy approach (also known as TCR-T) in March. The combined data readout during early phases of dose escalation for the ACTengine\u00ae programs, IMA201, IMA202 and IMA203, indicated first anti-tumor activity with tumor shrinkage observed in 8 out of 10 patients including one unconfirmed partial response as of data cut-off. This was consistent with the observed robust engraftment, persistence and tumor infiltration of infused ACTengine\u00ae T cells. Overall, the product candidates demonstrated a manageable safety and tolerability profile. <\/li>\n<li style=\"text-align:justify\">The ACTengine\u00ae trials continue to recruit according to plan with eight trial sites active in both Europe and the US. A data update is expected in H2 2021 with additional patients being treated, including initial data from patients treated at the target dose.<\/li>\n<li style=\"text-align:justify\">The fourth program of the ACTengine\u00ae IMA200 series, IMA204, is directed at the novel tumor stroma target COL6A3 exon 6 expressed in a large variety of solid cancers. IMA204 is utilizing a next-generation CD8-independent T cell receptor. Following a scientific advice meeting<sup>2<\/sup> with Paul-Ehrlich-Institute (PEI) in May, the Federal German regulatory authority, submission of a clinical trial application (CTA) remains on track for Q4 2021.\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qMZIvZqxTAyp_TILwdTXSebpsdcOzFHj-_T2nOmABwyoR8fvrj6jbyB4AO6LqGKwbw_kCiYSU3fgUKwe3wzFUvTNw-KGxu8Cccf07o3GvAA6Vvee_GGliBrCICgDzDyF\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <em>TCR Bispecifics Progra<\/em><br \/>\n          <em>ms<\/em><br \/>\n        <\/a>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">IMA402 \u2013 Immatics provided <a href=\"https:\/\/investors.immatics.com\/news-releases\/news-release-details\/immatics-presents-preclinical-proof-concept-data-tcr-0\" rel=\"nofollow noopener\" target=\"_blank\">preclinical proof-of-concept data <\/a><a href=\"https:\/\/investors.immatics.com\/news-releases\/news-release-details\/immatics-presents-preclinical-proof-concept-data-tcr-0\" rel=\"nofollow noopener\" target=\"_blank\">for<\/a><a href=\"https:\/\/investors.immatics.com\/news-releases\/news-release-details\/immatics-presents-preclinical-proof-concept-data-tcr-0\" rel=\"nofollow noopener\" target=\"_blank\"> its second TCER\u00ae program, IMA402<\/a>, at the Annual PEGS Boston Protein Engineering and Cell Therapy Summit in May. The IMA402 candidate targets an Immatics-validated peptide derived from PRAME, a protein that is frequently expressed in many solid cancers, thereby supporting the program\u2019s potential to address a broad cancer patient population. IMA402 demonstrated tumor cell killing <em>in vitro<\/em> and lead to consistent tumor reduction including complete regression of established tumors in an <em>in vivo<\/em> mouse model. Immatics has selected a clinical lead candidate for the IMA402 program and initiated manufacturing activities to  advance this program towards the Investigational New Drug (IND) stage and clinical development.<\/li>\n<li style=\"text-align:justify\">The company\u2019s first TCER\u00ae program, IMA401 remains on track for submission of a clinical trial application (CTA) by year end 2021. The company had announced <a href=\"https:\/\/investors.immatics.com\/news-releases\/news-release-details\/immatics-presents-preclinical-proof-concept-data-tcr-bispecifics\" rel=\"nofollow noopener\" target=\"_blank\">preclinical proof-of-concept data for IMA401<\/a> in last quarter of 2020.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>First Quarter 2021 Financial Results<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>Cash Position:<\/em> Cash and cash equivalents as well as other financial assets total \u20ac216.7 million ($254.0 million<sup>1<\/sup>) as of March 31, 2021. compared to \u20ac232.0 million ($272.0 million<sup>1<\/sup>) as of December 31, 2020. <\/p>\n<p align=\"justify\">\n        <em>Revenue:<\/em> Total revenue, consisting of revenue from collaboration agreements, was \u20ac7.4 million ($8.7 million<sup>1<\/sup>) for the three months ended March 31, 2021, compared to \u20ac7.0 million ($8.2 million<sup>1<\/sup>) for the three months ended March 31, 2020. <\/p>\n<p align=\"justify\">\n        <em>Research and Development Expenses:<\/em> R&amp;D expenses were \u20ac23.0 million ($27.0 million<sup>1<\/sup>) for the three months ended March 31, 2021, compared to \u20ac12.2 million ($14.4 million<sup>1<\/sup>) for the three months ended March 31, 2020. The increase is mainly due to increased share-based compensation (\u20ac4.5 million; $5.3 million<sup>1<\/sup>) as well as higher operating expenses due to increased clinical and manufacturing activities. <\/p>\n<p align=\"justify\">\n        <em>General and Administrative Expenses: <\/em>G&amp;A expenses were \u20ac8.4 million ($9.9 million<sup>1<\/sup>) for the three months ended March 31, 2021, compared to \u20ac6.2 million ($7.3 million<sup>1<\/sup>) for the three months ended March 31, 2020. The increase is mainly due to increased share-based compensation (\u20ac3.1 million; $3.7 million<sup>1<\/sup>), partly offset by one-time transaction costs of the NASDAQ listing in connection with the ARYA merger in July 2020. <\/p>\n<p align=\"justify\">\n        <em>Net Loss:<\/em> Net loss was \u20ac21.6 million ($25.3 million<sup>1<\/sup>) for the three months ended March 31, 2021, compared to \u20ac8.6 million ($10.1 million<sup>1<\/sup>) for the three months ended March 31, 2020. <\/p>\n<p align=\"justify\">\n        <em>Upcoming Investor Conferences<\/em>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">Jefferies Virtual Healthcare Conference \u2013 June 1-3, 2021<\/li>\n<li style=\"text-align:justify\">Goldman Sachs 42nd Annual Global Healthcare Conference \u2013 June 8-11, 2021<\/li>\n<\/ul>\n<p align=\"justify\">To see the full list of events and presentations, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kzDshI0ZoeVhhMKNjFyqCoJnn8_tkTLPwk_jhklDeLwpwkUVrXSr7vhtF4qnPttWVvBRpkx7z1kdNCOPH-oohUOJKLz7-CFK1OvS_-WO23dg8rG7Uk095CCejhGJ66VL2MwnT3rPTvyNjFwI6FYlHRxuylTyw2a26o5bcZBnQQA=\" rel=\"nofollow noopener\" target=\"_blank\">www.investors.immatics.com\/events-presentations<\/a>. <br \/>Full financial statements can be found in the current report on Form 6-K filed with the Securities and Exchange Commission (SEC) and published on the SEC website under <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=h2i8NjYW8QFkJcD0CsWnkeKMNA79cKF81n9efwp-r3MuHETpmoMBbQn2RX7fKJujjBCKm4bNVJMUsHUKM9TB6nFvds4JYsTIiA3_KNYqUhY=\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.sec.gov\/<\/a>.<\/p>\n<p align=\"justify\">\n        <sup>1 <\/sup>All amounts translated using the exchange rate published by the European Central Bank in effect as of March 31, 2021 (1 EUR = 1.1725 USD).<br \/><sup>2<\/sup> Equivalent to a pre-IND meeting at FDA.<\/p>\n<p align=\"justify\">\n        <strong>About ACTengine\u00ae IMA200 series<\/strong><br \/>\n        <br \/>Each of the product candidates of the IMA200 series is based on Immatics\u2019 proprietary ACTengine\u00ae approach in which the patient\u2019s own T cells are genetically engineered to express a novel, proprietary TCR directed against a defined cancer target. The modified T cells are then reinfused into the patient to attack the tumor, an approach also known as TCR-T. ACTengine\u00ae programs IMA201, IMA202 and IMA203 are currently in clinical development for the treatment of solid tumor indications, both in the US and in Germany.  All ACTengine\u00ae product candidates can be rapidly manufactured utilizing a proprietary manufacturing process designed to enhance T cell engraftment and persistence <em>in vivo.<\/em><br \/>The ACTengine\u00ae T cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with UTHealth and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT). <\/p>\n<p align=\"justify\">\n        <strong>About TCER\u00ae<\/strong><br \/>\n        <br \/>Immatics\u2019 TCER\u00ae molecules are antibody-like \u201coff-the-shelf\u201d biologics that leverage the body\u2019s immune system by redirecting and activating T cells towards cancer cells expressing a specific tumor target. To do so, the proprietary biologics are engineered to have two binding regions. The first region contains an affinity- and stability-improved TCR that binds specifically to the cancer target on the cell surface presented by a human leukocyte antigen (HLA) molecule. The second region is derived from an antibody domain that recruits endogenous T cells to the tumor to become activated. The design of the TCER\u00ae molecules enables the activation of any T cell in the body to attack the tumor, regardless of the T cells\u2019 intrinsic specificity. In addition, the TCER\u00ae molecule has a Fc-part conferring stability, half-life extension and enhanced manufacturability. <\/p>\n<p align=\"justify\">\n        <strong>About Immatics<\/strong><br \/>\n        <br \/>Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.<\/p>\n<p align=\"justify\">Immatics intends to use its website <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kzDshI0ZoeVhhMKNjFyqCjkV-0JAuV7h_QqaaisMsadAP0Fkrt_Ui-GTRygPMSNAJhXlPecoQsuhm8dElJmfBg==\" rel=\"nofollow noopener\" target=\"_blank\">www.immatics.com<\/a> as a means of disclosing material non-public information. For regular updates you can also follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wRbq5w4Cg9wSE7x9l1ncPm03e0efCadnga2AFEW8xBx0T9XU4KTQxDrje9AeP_VcjkFQ7-LV6ORgqJvSmbm4AQ==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l8etQ1vxe3ZR0-YvqJRC8UQ1gKgo_lnfEzy0QI7_NF4SQMqJLQMU0X1M7qZva-84EyQPJJZNqLHykasRvxgw5eR6RwI20zGKpzg_kkcEjzKP1f7-ktOrP2AHgC5GRFvu\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events or Immatics\u2019 future financial or operating performance. For example, statements concerning the timing of product candidates and Immatics\u2019 focus on partnerships to advance its strategy are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as \u201cmay\u201d, \u201cshould\u201d, \u201cexpect\u201d, \u201cintend\u201d, \u201cwill\u201d, \u201cestimate\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201cpredict\u201d, \u201cpotential\u201d or \u201ccontinue\u201d, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Immatics and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management&#8217;s control including general economic conditions and other risks, uncertainties and factors set forth in filings with the SEC. Nothing in this presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Immatics undertakes no duty to update these forward-looking statements.<\/p>\n<p align=\"justify\">\n        <strong>For more information, please contact:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;border-collapse:collapse\">\n<tr>\n<td style=\"width:339.87px;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>For <\/strong><br \/>\n            <strong>M<\/strong><br \/>\n            <strong>edia <\/strong><br \/>\n            <strong>I<\/strong><br \/>\n            <strong>nquiries<\/strong>\n          <\/td>\n<td style=\"width:283.47px;vertical-align: top\">\n            <strong>Investor Relations Contact<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:339.87px;text-align: justify;vertical-align: middle;vertical-align: top\">    Jacob Verghese or Stephanie May    <\/td>\n<td style=\"width:283.47px;vertical-align: top\">    John Graziano    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:339.87px;text-align: justify;vertical-align: middle;vertical-align: top\">    Trophic Communications    <\/td>\n<td style=\"width:283.47px;vertical-align: top\">    Solebury Trout    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:339.87px;text-align: justify;vertical-align: middle;vertical-align: top\">    Phone: +49 89 2388 7731     <\/td>\n<td style=\"width:283.47px;vertical-align: top\">    Phone: +1 646 378 2942    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:339.87px;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <a href=\"mailto:immatics@trophic.eu\" rel=\"nofollow noopener\" target=\"_blank\">immatics@trophic.eu<\/a>\n          <\/td>\n<td style=\"width:283.47px;vertical-align: top\">\n            <a href=\"mailto:jgraziano@soleburytrout.com\" rel=\"nofollow noopener\" target=\"_blank\">jgraziano@soleburytrout.com<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;border-collapse:collapse\">\n<tr>\n<td style=\"width:340.2px;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <strong>Immatics N.V.<\/strong>\n          <\/td>\n<td style=\"width:283.14px;vertical-align: top\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:340.2px;text-align: justify;vertical-align: middle;vertical-align: top\">    Anja Heuer    <\/td>\n<td style=\"width:283.14px;text-align: justify;vertical-align: middle;vertical-align: top\">    Jordan Silverstein    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:340.2px;text-align: justify;vertical-align: middle;vertical-align: top\">    Corporate Communications    <\/td>\n<td style=\"width:283.14px;text-align: justify;vertical-align: middle;vertical-align: top\">    Head of Strategy    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:340.2px;text-align: justify;vertical-align: middle;vertical-align: top\">    Phone: +49 89 540415-606     <\/td>\n<td style=\"width:283.14px;vertical-align: top\">    Phone: +1 281 810 7545    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:340.2px;text-align: justify;vertical-align: middle;vertical-align: top\">\n            <a href=\"mailto:media@immatics.com\" rel=\"nofollow noopener\" target=\"_blank\">media@immatics.com<\/a>\n          <\/td>\n<td style=\"width:283.14px;vertical-align: top\">\n            <a href=\"mailto:InvestorRelations@immatics.com\" rel=\"nofollow noopener\" target=\"_blank\">InvestorRelations@immatics.com<\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        <br \/>\u00a0<\/p>\n<p>\n        <br \/>\u00a0<\/p>\n<p>\n        <strong>Unaudited Condensed Consolidated Statement of Financial Position of Immatics N.V.<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/p>\n<p>\u00a0<\/td>\n<td colspan=\"3\" style=\"width:233.6px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>As of<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>March 31, 2021<\/strong>\n          <\/td>\n<td style=\"width:17.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:115.27px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>December 31, 2020<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:233.6px;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>(Euros in thousands)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>Assets<\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:100.6px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:17.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:115.27px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>Current assets<\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:100.6px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:17.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:115.27px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Cash and cash equivalents<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">195,333<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">207,530<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Other financial assets<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">21,322<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">24,448<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Accounts receivable<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">575<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">1,250<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Other current assets<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">4,766<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">5,763<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>Total current assets<\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;border-top: solid black 1pt;vertical-align: top\">\n            <strong>221,996<\/strong>\n          <\/td>\n<td style=\"width:17.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;border-top: solid black 1pt;vertical-align: top\">\n            <strong>238,991<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>Non-current assets<\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:100.6px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:115.27px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Property, plant and equipment<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">7,981<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">7,868<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Intangible assets<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">920<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">914<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Right-of-use assets<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">6,286<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">6,149<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Other non-current assets<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">589<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">724<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>Total non-current assets<\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;border-top: solid black 1pt;vertical-align: top\">\n            <strong>15,776<\/strong>\n          <\/td>\n<td style=\"width:17.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;border-top: solid black 1pt;vertical-align: top\">\n            <strong>15,655<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>Total assets<\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>237,772<\/strong>\n          <\/td>\n<td style=\"width:17.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>254,646<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>Liabilities and shareholders&#8217; deficit<\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>Current liabilities<\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Provisions<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">971<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">51<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Accounts payable<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">10,304<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">10,052<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Deferred revenue<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">53,334<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">46,600<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Lease liabilities<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">1,978<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">1,881<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Other current liabilities<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">1,416<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">2.025<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>Total current liabilities<\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;border-top: solid black 1pt;vertical-align: top\">\n            <strong>68,003<\/strong>\n          <\/td>\n<td style=\"width:17.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;border-top: solid black 1pt;vertical-align: top\">\n            <strong>60,609<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>Non-current liabilities<\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Deferred revenue<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">71,707<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">85,475<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Lease liabilities<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">4,375<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">4,306<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>Total non-current liabilities<\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;border-top: solid black 1pt;vertical-align: top\">\n            <strong>76,082<\/strong>\n          <\/td>\n<td style=\"width:17.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;border-top: solid black 1pt;vertical-align: top\">\n            <strong>89,781<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>Shareholders&#8217; equity<\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Share capital<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">629<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">629<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Share premium<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">581,643<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">573,339<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Accumulated deficit<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">(483,851)<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">(462,253)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Other reserves<\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;vertical-align: top\">(4,734)<\/td>\n<td style=\"width:17.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;vertical-align: top\">(7,459)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>Total shareholders&#8217; equity<\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;border-top: solid black 1pt;vertical-align: top\">\n            <strong>93,687<\/strong>\n          <\/td>\n<td style=\"width:17.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;border-top: solid black 1pt;vertical-align: top\">\n            <strong>104,256<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:282.07px;vertical-align: top\">\n            <strong>Total liabilities and shareholders&#8217; equity <\/strong>\n          <\/td>\n<td style=\"width:22.74px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:100.6px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>237,772<\/strong>\n          <\/td>\n<td style=\"width:17.74px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:115.27px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>254,646<\/strong>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        <br \/>\u00a0<\/p>\n<p>\n        <strong>Unaudited Condensed Consolidated Statement of Loss of Immatics N.V.<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:27.78%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.09%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.09%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"12\" style=\"width:17.89%;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Three months ended<\/strong><br \/>\n            <br \/>\n            <strong>March 31,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.09%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.09%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"5\" style=\"width:8.97%;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>2021<\/strong>\n          <\/td>\n<td style=\"width:0.39%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.22%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"5\" style=\"width:8.31%;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>2020<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.09%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.09%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"12\" style=\"width:17.89%;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>(Euros in thousands,<\/strong><br \/>\n            <br \/>\n            <strong>except share and per<\/strong><br \/>\n            <br \/>\n            <strong>share data)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\u00a0<\/p>\n<p>Revenue from collaboration agreements<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">7,403<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">7,040<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Research and development expenses<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">(23,049)<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">(12,246)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">General and administrative expenses<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">(8,431)<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">(6,188)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Other income<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">239<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">113<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\n            <strong>Operating result<\/strong>\n          <\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(23,838)<\/strong>\n          <\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(11,281)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Financial income<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">3,464<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">2,730<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Financial expenses<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">(1,224)<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">(29)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\n            <strong>Financial result<\/strong>\n          <\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>2,240<\/strong>\n          <\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>2,701<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\n            <strong>Loss before taxes<\/strong>\n          <\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(21,598)<\/strong>\n          <\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(8,580)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Taxes on income<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">(<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\n            <strong>Net loss<\/strong>\n          <\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(21,598)<\/strong>\n          <\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(8,580)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;text-align: justify;vertical-align: middle;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Attributable to:<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;text-align: center;vertical-align: middle;vertical-align: top\">Equity holders of the parent<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(21,598)<\/strong>\n          <\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(8,306)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: top\"> Non-controlling interest<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">(274)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\n            <strong>Net loss<\/strong>\n          <\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(21,598)<\/strong>\n          <\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(8,580)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">\n            <strong>Net loss per share\u2014basic and diluted<\/strong>\n          <\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(0.34)<\/strong>\n          <\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(0.25)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:27.78%;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: middle;text-align: left;padding-left: 15.0px;vertical-align: top\">Weighted average shares outstanding\u2014basic and diluted<\/td>\n<td style=\"width:4.14%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.28%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"4\" style=\"width:9.51%;text-align: right;vertical-align: middle;vertical-align: top\">62,908,791<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:0.12%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:7.42%;text-align: right;vertical-align: middle;vertical-align: top\">33,093,838<\/td>\n<\/tr>\n<\/table>\n<p>\n        <br \/>\u00a0<\/p>\n<p>\n        <strong>Unaudited Condensed Consolidated Statement of Comprehensive Loss of Immatics N.V.<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:20.94%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:4.76%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.37%;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:22.93%;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Three months ended March 31,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.94%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:4.76%;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>\u00a0Notes<\/strong>\n          <\/td>\n<td style=\"width:1.37%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:10.2%;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>2021<\/strong>\n          <\/td>\n<td style=\"width:1.81%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:10.92%;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>2020<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.94%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:4.76%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:1.37%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td colspan=\"3\" style=\"width:22.93%;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>(Euros in thousands)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.94%;vertical-align: top\">\n            <strong>Net Loss <\/strong>\n          <\/td>\n<td style=\"width:4.76%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:1.37%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:10.2%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(21,598)<\/strong>\n          <\/td>\n<td style=\"width:1.81%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:10.92%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(8,580)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.94%;vertical-align: top\">\n            <strong>Other comprehensive loss<\/strong>\n          <\/td>\n<td style=\"width:4.76%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:1.37%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:10.2%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.81%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:10.92%;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.94%;vertical-align: top\">Items that may be reclassified subsequently to profit or loss, net of tax<\/td>\n<td style=\"width:4.76%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.37%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:10.2%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:1.81%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:10.92%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.94%;vertical-align: top\">Currency translation differences from foreign operations<\/td>\n<td style=\"width:4.76%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.37%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:10.2%;text-align: right;vertical-align: middle;vertical-align: top\">2,725<\/td>\n<td style=\"width:1.81%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:10.92%;text-align: right;vertical-align: middle;vertical-align: top\">(692)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.94%;vertical-align: top\">\n            <strong>Total comprehensive loss for the period<\/strong>\n          <\/td>\n<td style=\"width:4.76%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:1.37%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:10.2%;text-align: right;vertical-align: middle;border-top: solid black 1pt;vertical-align: top\">\n            <strong>(18,873)<\/strong>\n          <\/td>\n<td style=\"width:1.81%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:10.92%;text-align: right;vertical-align: middle;border-top: solid black 1pt;vertical-align: top\">\n            <strong>(9,272)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.94%;vertical-align: top\">\n            <strong>Attributable to: <\/strong>\n          <\/td>\n<td style=\"width:4.76%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:1.37%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:10.2%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.81%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:10.92%;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.94%;text-align: right;vertical-align: middle;vertical-align: top\">Equity holders of the parent<\/td>\n<td style=\"width:4.76%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.37%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:10.2%;text-align: right;vertical-align: middle;vertical-align: top\">(18,873)<\/td>\n<td style=\"width:1.81%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:10.92%;text-align: right;vertical-align: middle;vertical-align: top\">(8,998)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.94%;text-align: right;vertical-align: middle;vertical-align: top\">Non-controlling interest<\/td>\n<td style=\"width:4.76%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:1.37%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:10.2%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:1.81%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:10.92%;text-align: right;vertical-align: middle;vertical-align: top\">(274)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:20.94%;vertical-align: top\">\n            <strong>Total comprehensive loss for the period<\/strong>\n          <\/td>\n<td style=\"width:4.76%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:1.37%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:10.2%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>(18,873)<\/strong>\n          <\/td>\n<td style=\"width:1.81%;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:10.92%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>(9,272)<\/strong>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        <br \/>\u00a0<\/p>\n<p>\n        <strong>Unaudited Condensed Consolidated Statement of Cash Flows of Immatics N.V. <\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;margin-left:3.5pt;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:207.74px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Three months ended March 31,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:97.14px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>2021<\/strong>\n          <\/td>\n<td style=\"width:21.8px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:88.8px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>2020<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td colspan=\"3\" style=\"width:207.74px;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>(Euros in thousands)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:97.14px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>Cash flows from operating activities<\/strong>\n          <\/td>\n<td style=\"width:97.14px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:21.8px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:88.8px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>Loss before taxation<\/strong>\n          <\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(21,598)<\/strong>\n          <\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(8,580)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>Adjustments for:<\/strong>\n          <\/td>\n<td style=\"width:97.14px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Interest income<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">(49)<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">(319)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Depreciation and amortization<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">1,094<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">1,048<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Interest expense<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">70<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">28<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Equity settled share-based payment<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">8,304<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">39<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">MD Anderson compensation expense<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">37<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">(Decrease) Increase in other liabilities resulting from share appreciation rights<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">689<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Net foreign exchange differences<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">318<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">(786)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>Changes in working capital<\/strong>\n          <\/td>\n<td style=\"width:97.14px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Decrease (increase) in accounts receivable <\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">676<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">625<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">(Increase) decrease in other assets <\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">1,207<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">(372)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Increase in accounts payable and other current liabilities<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">(6,645)<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">(3,990)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Interest received<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">36<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">159<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Interest paid<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">(70)<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">(28)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>Net cash provided by<\/strong><br \/>\n            <strong>\/(<\/strong><br \/>\n            <strong>used in) operating activities<\/strong>\n          <\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>(16,657)<\/strong>\n          <\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>(11,450)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>Cash flows from investing activities<\/strong>\n          <\/td>\n<td style=\"width:97.14px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Payments for property, plant and equipment<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">(565)<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">(2,382)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Cash paid for investments classified in Other financial assets<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">(21,322)<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">(32,859)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Cash received from maturity of investments classified in Other financial assets<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">24,448<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">16,023<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Payments for intangible assets<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">(6)<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">(5)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Proceeds from disposal of property, plant and equipment<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">4<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>Net cash provided by<\/strong><br \/>\n            <strong>\/(<\/strong><br \/>\n            <strong>used in) investing activities<\/strong>\n          <\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>2,559<\/strong>\n          <\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>(19,223)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>Cash flows from financing activities<\/strong>\n          <\/td>\n<td style=\"width:97.14px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Payments for leases<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">(482)<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">(611)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>Net cash provided by<\/strong><br \/>\n            <strong>\/(<\/strong><br \/>\n            <strong>used in) financing activities<\/strong>\n          <\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>(482)<\/strong>\n          <\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>(611)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>Net decrease in cash and cash equivalents<\/strong>\n          <\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>(14,580)<\/strong>\n          <\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>(31,284)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>Cash and cash equivalents at beginning of period<\/strong>\n          <\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>207,530<\/strong>\n          <\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>103,353<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">Effects of exchange rate changes on cash and cash equivalents<\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;vertical-align: top\">2,383<\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;vertical-align: top\">133<\/td>\n<\/tr>\n<tr>\n<td style=\"width:369.07px;vertical-align: top\">\n            <strong>Cash and cash equivalents at end of period<\/strong>\n          <\/td>\n<td style=\"width:97.14px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>195,333<\/strong>\n          <\/td>\n<td style=\"width:21.8px;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:88.8px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>72,202<\/strong>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\u00a0<\/p>\n<p>\n        <strong>Unaudited Condensed Consolidated Statement of Changes in Shareholders\u2019 equity (deficit) of Immatics N.V.<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">\n            <strong>(Euros in thousands)<\/strong>\n          <\/td>\n<td style=\"width:4.38%;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Share capital<\/strong>\n          <\/td>\n<td style=\"width:5.17%;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Share premium<\/strong>\n          <\/td>\n<td style=\"width:5.56%;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Accumulated deficit<\/strong>\n          <\/td>\n<td style=\"width:4.77%;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Other reserves<\/strong>\n          <\/td>\n<td style=\"width:6.34%;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Total equity (deficit) attributable to shareholders of the parent<\/strong>\n          <\/td>\n<td style=\"width:4.75%;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Non-controlling interest<\/strong>\n          <\/td>\n<td style=\"width:5.55%;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>Total share-holders&#8217; equity (deficit)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">\n            <strong>Balance as of January 1, 2020<\/strong>\n          <\/td>\n<td style=\"width:4.38%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>1,164<\/strong>\n          <\/td>\n<td style=\"width:5.17%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>190,945<\/strong>\n          <\/td>\n<td style=\"width:5.56%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(233,194)<\/strong>\n          <\/td>\n<td style=\"width:4.77%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(770)<\/strong>\n          <\/td>\n<td style=\"width:6.34%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(41,855)<\/strong>\n          <\/td>\n<td style=\"width:4.75%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>1,020<\/strong>\n          <\/td>\n<td style=\"width:5.55%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(40,835)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">Other comprehensive loss<\/td>\n<td style=\"width:4.38%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:5.17%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:5.56%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:4.77%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(692)<\/strong>\n          <\/td>\n<td style=\"width:6.34%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(692)<\/strong>\n          <\/td>\n<td style=\"width:4.75%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:5.55%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(692)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">Net loss<\/td>\n<td style=\"width:4.38%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:5.17%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:5.56%;text-align: right;vertical-align: middle;vertical-align: top\">(8,306)<\/td>\n<td style=\"width:4.77%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:6.34%;text-align: right;vertical-align: middle;vertical-align: top\">(8,306)<\/td>\n<td style=\"width:4.75%;text-align: right;vertical-align: middle;vertical-align: top\">(274)<\/td>\n<td style=\"width:5.55%;text-align: right;vertical-align: middle;vertical-align: top\">(8,580)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">\n            <strong>Comprehensive loss for the year<\/strong>\n          <\/td>\n<td style=\"width:4.38%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>&#8211;<\/strong>\n          <\/td>\n<td style=\"width:5.17%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>&#8211;<\/strong>\n          <\/td>\n<td style=\"width:5.56%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(8,306)<\/strong>\n          <\/td>\n<td style=\"width:4.77%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(692)<\/strong>\n          <\/td>\n<td style=\"width:6.34%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(8,998)<\/strong>\n          <\/td>\n<td style=\"width:4.75%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(274)<\/strong>\n          <\/td>\n<td style=\"width:5.55%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(9,272)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">Equity-settled tandem awards<\/td>\n<td style=\"width:4.38%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:5.17%;text-align: right;vertical-align: middle;vertical-align: top\">39<\/td>\n<td style=\"width:5.56%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:4.77%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:6.34%;text-align: right;vertical-align: middle;vertical-align: top\">39<\/td>\n<td style=\"width:4.75%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:5.55%;text-align: right;vertical-align: middle;vertical-align: top\">39<\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">MD Anderson milestone compensation expense<\/td>\n<td style=\"width:4.38%;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:5.17%;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:5.56%;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:4.77%;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:6.34%;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:4.75%;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">37<\/td>\n<td style=\"width:5.55%;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">37<\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">\n            <strong>Balance as of March 31, 2020<\/strong>\n          <\/td>\n<td style=\"width:4.38%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>1,164<\/strong>\n          <\/td>\n<td style=\"width:5.17%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>190,984<\/strong>\n          <\/td>\n<td style=\"width:5.56%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>(241,500)<\/strong>\n          <\/td>\n<td style=\"width:4.77%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>(1,462)<\/strong>\n          <\/td>\n<td style=\"width:6.34%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>(50,814)<\/strong>\n          <\/td>\n<td style=\"width:4.75%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>783<\/strong>\n          <\/td>\n<td style=\"width:5.55%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>(50,031)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:4.38%;border-top: double black 3pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:5.17%;border-top: double black 3pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:5.56%;border-top: double black 3pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:4.77%;border-top: double black 3pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:6.34%;border-top: double black 3pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:4.75%;border-top: double black 3pt;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:5.55%;border-top: double black 3pt;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">\n            <strong>Balance as of January 1, 2021<\/strong>\n          <\/td>\n<td style=\"width:4.38%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>629<\/strong>\n          <\/td>\n<td style=\"width:5.17%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>573,339<\/strong>\n          <\/td>\n<td style=\"width:5.56%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(462,253)<\/strong>\n          <\/td>\n<td style=\"width:4.77%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(7,459)<\/strong>\n          <\/td>\n<td style=\"width:6.34%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>104,256<\/strong>\n          <\/td>\n<td style=\"width:4.75%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>&#8211;<\/strong>\n          <\/td>\n<td style=\"width:5.55%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>104,256<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">Other comprehensive loss<\/td>\n<td style=\"width:4.38%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>&#8211;<\/strong>\n          <\/td>\n<td style=\"width:5.17%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>&#8211;<\/strong>\n          <\/td>\n<td style=\"width:5.56%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong> &#8211;<\/strong>\n          <\/td>\n<td style=\"width:4.77%;text-align: right;vertical-align: middle;vertical-align: top\">2,725<\/td>\n<td style=\"width:6.34%;text-align: right;vertical-align: middle;vertical-align: top\">2,725<\/td>\n<td style=\"width:4.75%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong> &#8211;<\/strong>\n          <\/td>\n<td style=\"width:5.55%;text-align: right;vertical-align: middle;vertical-align: top\">2,725<\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">Net loss<\/td>\n<td style=\"width:4.38%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:5.17%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:5.56%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(21,598)<\/strong>\n          <\/td>\n<td style=\"width:4.77%;text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<td style=\"width:6.34%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(21,598)<\/strong>\n          <\/td>\n<td style=\"width:4.75%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>&#8211; <\/strong>\n          <\/td>\n<td style=\"width:5.55%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(21,598)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">\n            <strong>Comprehensive loss for the year<\/strong>\n          <\/td>\n<td style=\"width:4.38%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>&#8211;<\/strong>\n          <\/td>\n<td style=\"width:5.17%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>&#8211;<\/strong>\n          <\/td>\n<td style=\"width:5.56%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(21,598)<\/strong>\n          <\/td>\n<td style=\"width:4.77%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>2,725<\/strong>\n          <\/td>\n<td style=\"width:6.34%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(18,873)<\/strong>\n          <\/td>\n<td style=\"width:4.75%;vertical-align: top\">\u00a0<\/td>\n<td style=\"width:5.55%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>(18,873)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">Equity-settled share-based compensation<\/td>\n<td style=\"width:4.38%;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>&#8211;<\/strong>\n          <\/td>\n<td style=\"width:5.17%;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">8,304<\/td>\n<td style=\"width:5.56%;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>&#8211;<\/strong>\n          <\/td>\n<td style=\"width:4.77%;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>&#8211;<\/strong>\n          <\/td>\n<td style=\"width:6.34%;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">8,304<\/td>\n<td style=\"width:4.75%;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">\n            <strong>&#8211;<\/strong>\n          <\/td>\n<td style=\"width:5.55%;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;vertical-align: top\">8,304<\/td>\n<\/tr>\n<tr>\n<td style=\"width:13.49%;vertical-align: top\">\n            <strong>Balance as of March 31, 2021<\/strong>\n          <\/td>\n<td style=\"width:4.38%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>629<\/strong>\n          <\/td>\n<td style=\"width:5.17%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>581,643<\/strong>\n          <\/td>\n<td style=\"width:5.56%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>(483,851)<\/strong>\n          <\/td>\n<td style=\"width:4.77%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>(4,734)<\/strong>\n          <\/td>\n<td style=\"width:6.34%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>93,687<\/strong>\n          <\/td>\n<td style=\"width:4.75%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>&#8211;<\/strong>\n          <\/td>\n<td style=\"width:5.55%;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: double 15px 3pt;vertical-align: top\">\n            <strong>93,687<\/strong>\n          <\/td>\n<\/tr>\n<\/table>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ5NTU2NyM0MDA5NDE5MDQjMjE5NjA3MQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/release\/track\/d8566c08-e682-4188-b024-bce55b0a5f07\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>D ata update for ongoing ACTengine\u00ae IMA200 clinical trial series demonstrate d first anti-tumor activity in heavily pre-treated solid cancer patients during early phases of dose escalation Next ACTengine\u00ae data update for dose level s 2 and 3 on track for H2 2021 P reclinical proof-of-concept for second TCR Bispecifics (TCER\u00ae) program IMA402 against the frequently expressed cancer target PRAME announced Cash and cash equivalents as well as o ther financial assets of $254.0 million ( \u20ac 2 1 6.7 million 1 ) as of March 3 1 , 202 1 provide cash reach into 2023 Tuebingen , Germany and Houston, TX , May 18 , 20 2 1 \u2013 ImmaticsN.V. (NASDAQ: IMTX; \u201cImmatics\u201d), a clinical-stage biopharmaceutical company active in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immatics Announces First Quarter 2021 Financial Results and Business Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-494799","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immatics Announces First Quarter 2021 Financial Results and Business Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immatics Announces First Quarter 2021 Financial Results and Business Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"D ata update for ongoing ACTengine\u00ae IMA200 clinical trial series demonstrate d first anti-tumor activity in heavily pre-treated solid cancer patients during early phases of dose escalation Next ACTengine\u00ae data update for dose level s 2 and 3 on track for H2 2021 P reclinical proof-of-concept for second TCR Bispecifics (TCER\u00ae) program IMA402 against the frequently expressed cancer target PRAME announced Cash and cash equivalents as well as o ther financial assets of $254.0 million ( \u20ac 2 1 6.7 million 1 ) as of March 3 1 , 202 1 provide cash reach into 2023 Tuebingen , Germany and Houston, TX , May 18 , 20 2 1 \u2013 ImmaticsN.V. (NASDAQ: IMTX; \u201cImmatics\u201d), a clinical-stage biopharmaceutical company active in &hellip; Continue reading &quot;Immatics Announces First Quarter 2021 Financial Results and Business Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-18T11:04:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ5NTU2NyM0MDA5NDE5MDQjMjE5NjA3MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immatics-announces-first-quarter-2021-financial-results-and-business-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immatics-announces-first-quarter-2021-financial-results-and-business-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immatics Announces First Quarter 2021 Financial Results and Business Update\",\"datePublished\":\"2021-05-18T11:04:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immatics-announces-first-quarter-2021-financial-results-and-business-update\\\/\"},\"wordCount\":2168,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immatics-announces-first-quarter-2021-financial-results-and-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ5NTU2NyM0MDA5NDE5MDQjMjE5NjA3MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immatics-announces-first-quarter-2021-financial-results-and-business-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immatics-announces-first-quarter-2021-financial-results-and-business-update\\\/\",\"name\":\"Immatics Announces First Quarter 2021 Financial Results and Business Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immatics-announces-first-quarter-2021-financial-results-and-business-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immatics-announces-first-quarter-2021-financial-results-and-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ5NTU2NyM0MDA5NDE5MDQjMjE5NjA3MQ==\",\"datePublished\":\"2021-05-18T11:04:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immatics-announces-first-quarter-2021-financial-results-and-business-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immatics-announces-first-quarter-2021-financial-results-and-business-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immatics-announces-first-quarter-2021-financial-results-and-business-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ5NTU2NyM0MDA5NDE5MDQjMjE5NjA3MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ5NTU2NyM0MDA5NDE5MDQjMjE5NjA3MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immatics-announces-first-quarter-2021-financial-results-and-business-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immatics Announces First Quarter 2021 Financial Results and Business Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immatics Announces First Quarter 2021 Financial Results and Business Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/","og_locale":"en_US","og_type":"article","og_title":"Immatics Announces First Quarter 2021 Financial Results and Business Update - Market Newsdesk","og_description":"D ata update for ongoing ACTengine\u00ae IMA200 clinical trial series demonstrate d first anti-tumor activity in heavily pre-treated solid cancer patients during early phases of dose escalation Next ACTengine\u00ae data update for dose level s 2 and 3 on track for H2 2021 P reclinical proof-of-concept for second TCR Bispecifics (TCER\u00ae) program IMA402 against the frequently expressed cancer target PRAME announced Cash and cash equivalents as well as o ther financial assets of $254.0 million ( \u20ac 2 1 6.7 million 1 ) as of March 3 1 , 202 1 provide cash reach into 2023 Tuebingen , Germany and Houston, TX , May 18 , 20 2 1 \u2013 ImmaticsN.V. (NASDAQ: IMTX; \u201cImmatics\u201d), a clinical-stage biopharmaceutical company active in &hellip; Continue reading \"Immatics Announces First Quarter 2021 Financial Results and Business Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-18T11:04:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ5NTU2NyM0MDA5NDE5MDQjMjE5NjA3MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immatics Announces First Quarter 2021 Financial Results and Business Update","datePublished":"2021-05-18T11:04:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/"},"wordCount":2168,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ5NTU2NyM0MDA5NDE5MDQjMjE5NjA3MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/","name":"Immatics Announces First Quarter 2021 Financial Results and Business Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ5NTU2NyM0MDA5NDE5MDQjMjE5NjA3MQ==","datePublished":"2021-05-18T11:04:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ5NTU2NyM0MDA5NDE5MDQjMjE5NjA3MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ5NTU2NyM0MDA5NDE5MDQjMjE5NjA3MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immatics-announces-first-quarter-2021-financial-results-and-business-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immatics Announces First Quarter 2021 Financial Results and Business Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/494799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=494799"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/494799\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=494799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=494799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=494799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}